OCT macular changes in type 1 ROP following Ranibizumab injections.

IF 2.4 Q2 OPHTHALMOLOGY

International Journal of Retina and Vitreous Pub Date : 2025-04-17 DOI:10.1186/s40942-025-00664-7

Rawan Hosny, Jylan Gouda, Tamer A Macky, Ayman Khattab, Hany Mekkawy, Abdussalam M Abdullatif

{"title":"OCT macular changes in type 1 ROP following Ranibizumab injections.","authors":"Rawan Hosny, Jylan Gouda, Tamer A Macky, Ayman Khattab, Hany Mekkawy, Abdussalam M Abdullatif","doi":"10.1186/s40942-025-00664-7","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections.Methods: Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection. Central full thickness (CFT), inner retinal layer (IRL), and outer retinal layer (ORL) thickness measurements were taken from foveal center and parafoveal region.Results: 24 eyes of 12 infants were included in this study. There were no significant changes in the mean CFT and IRL thickness at 1 month (p = 0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9 ± 16, 96.1 ± 25 at baseline and one month respectively, p < 0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. Macular edema (ME) was observed in 12 eyes (50%) and was associated with smaller birth weight (p = 0.0290). There was no significant decrease in mean CFT in eyes with ME at 1 month (p = 0.13), with complete resolution in only 6 eyes (50%) during the study period. Regression of plus was associated with lower CFT (1 week and 1 month; p = 0.02 and 0.03, respectively).Conclusion: Ranibizumab treated eyes in type 1 show ORL thickening and differentiation but with inadequate resolution of ME.","PeriodicalId":14289,"journal":{"name":"International Journal of Retina and Vitreous","volume":"11 1","pages":"47"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Retina and Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40942-025-00664-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections.

Methods: Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection. Central full thickness (CFT), inner retinal layer (IRL), and outer retinal layer (ORL) thickness measurements were taken from foveal center and parafoveal region.

Results: 24 eyes of 12 infants were included in this study. There were no significant changes in the mean CFT and IRL thickness at 1 month (p = 0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9 ± 16, 96.1 ± 25 at baseline and one month respectively, p < 0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. Macular edema (ME) was observed in 12 eyes (50%) and was associated with smaller birth weight (p = 0.0290). There was no significant decrease in mean CFT in eyes with ME at 1 month (p = 0.13), with complete resolution in only 6 eyes (50%) during the study period. Regression of plus was associated with lower CFT (1 week and 1 month; p = 0.02 and 0.03, respectively).

Conclusion: Ranibizumab treated eyes in type 1 show ORL thickening and differentiation but with inadequate resolution of ME.

Abstract Image

查看原文本刊更多论文

注射雷尼单抗后1型ROP的OCT黄斑改变。

目的：探讨1型ROP患者注射雷尼单抗1个月后OCT黄斑的变化。方法：采用雷尼单抗注射的1型ROP早产儿为研究对象。在基线、注射后1周和1个月进行手持式OCT成像。中央全厚度（CFT），视网膜内层（IRL）和视网膜外层（ORL）厚度测量从中央凹中心和中央凹旁区域。结果：12例婴儿24只眼纳入本研究。1个月时CFT和IRL平均厚度无显著变化（p = 0.5和0.1）。然而，在1个月时，平均ORL厚度显著增加（基线时为69.9±16，基线时为96.1±25,1个月时为96.1±25）。结论：雷尼单抗治疗的1型眼显示ORL增厚和分化，但ME分辨率不足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Retina and Vitreous Medicine-Ophthalmology

CiteScore

3.50

自引率

4.30%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Retina and Vitreous focuses on the ophthalmic subspecialty of vitreoretinal disorders. The journal presents original articles on new approaches to diagnosis, outcomes of clinical trials, innovations in pharmacological therapy and surgical techniques, as well as basic science advances that impact clinical practice. Topical areas include, but are not limited to: -Imaging of the retina, choroid and vitreous -Innovations in optical coherence tomography (OCT) -Small-gauge vitrectomy, retinal detachment, chromovitrectomy -Electroretinography (ERG), microperimetry, other functional tests -Intraocular tumors -Retinal pharmacotherapy & drug delivery -Diabetic retinopathy & other vascular diseases -Age-related macular degeneration (AMD) & other macular entities